By Phoebe Starr
The PD-L1 inhibitor durvalumab (Imfinzi) showed an overall survival benefit in patients with unresectable stage III non–small-cell lung cancer (NSCLC) in the phase 3 PACIFIC trial Read More ›
By Phoebe Starr
A burning question is whether immunotherapy combinations will further improve outcomes compared with checkpoint inhibitor therapy alone—and if so, which combinations will rise to the top. Read More ›
By Phoebe Starr
The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) extended progression-free survival (PFS) versus standard chemotherapy as first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) and a high tumor mutational burden (TMB). This finding was unrelated to levels of PD-L1 expression, said Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York City. Read More ›